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Summary A new method with a low pH step to dissociate serum complexes has been developed to measure
serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies
HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by
the antibody CA125. Elevated HMFG1 was found in 56%, and elevated HMFG2 in 65% of 924 sera from 85
patients with ovarian cancer. CA125 was elevated in 85% of these sera. When the three markers were used in
conjunction, 95% of sera from patients with ovarian cancer were positive - compared with 7% in sera from
healthy control subjects. Therefore, the combination of HMFG1, HMFG2 and CA125 increases the
diagnostic accuracy. If all three markers are normal in a patient previously treated for ovarian cancer then no
further positive information regarding disease status can be obtained by ultrasound and CT scanning.
Early diagnosis of epithelial ovarian cancer is
desirable because it is associated with a better
prognosis (Young et al., 1982). It is also useful to
have a simple and cost effective way of monitoring
response to therapy. Until recently CT scanning has
been the most useful non-invasive method for
tumour detection (Johnson et al., 1983). Although
second-look laparotomy can provide further
information about disease status the procedure, in
itself, does not improve survival (Cohen et al.,
1983). Recently a radioimmunoassay has been
developed, incorporating monoclonal antibody
CA125, which is of value in monitoring the
response to therapy in approximately 85% of
patients with ovarian cancer (Bast et al., 1983;
Canney et al., 1984).
In this paper we describe a new method using a
panel of monoclonal antibodies that can be used to
measure tumour markers. In conjunction with
CA125 assay it provides a sensitive and specific
system for the detection and management of
epithelial ovarian cancer.
Patients and methods
Patients
HMFG1, HMFG2 and CA125 levels were
measured in 924 sera from 85 patients with histo-
logically proven epithelial ovarian cancer. Sera
from 5 patients with definite evidence of disease but
with negative HMFG1, HMFG2 and CA125 levels
were tested in a further assay measuring serum
placental alkaline phosphatase (PLAP) (Tucker et
al., 1985).
Sera from 150 apparently healthy blood donors
obtained from the Regional Blood Transfusion
Centre were assayed for HMFG1 and HMFG2.
Serum samples were stored at -20°C until required
for analysis. Sera were frozen and thawed once
only prior to assay.
The accompanying paper (Dhokia et al., 1986)
describes the results of serum assays for HMFGI
and HMFG2 antigens in sera from patients with
neoplastic and non-neoplastic breast, liver and
gastrointestinal diseases.
Chemotherapy schedules and patient assessment
were as previously reported (Canney et al., 1984).
HMFGJ and HMFG2 antibodies
These mouse IgGI antibodies were raised against a
delipidated preparation of the human milk fat
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globule. The mouse used for the development of
HMFG2 also received cultured milk epithelial cells
(Arklie et al., 1981).
ELISA method
It was suspected that one of the reasons for the
failure of existing conventional 'sandwich' ELISA
systems to detect small amounts of circulating
antigen is that the antigen is complexed specifically
or non-specifically with other serum components
and therefore escapes detection by antibody. One
way to expose the antigen is to disrupt complexes
using acidic conditions, e.g. with citric acid, pH 2.0
(Feller et al., 1985). We used phosphatase
conjugated antibody since this simplifies the
method (one step procedure) and minimises the
proportion of false positive results (Ishikawa et al.,
1983) (IQ [Biol Ltd., Cambridge).
Twenty pl of serum was added to 250,1d citrate
buffer (pH 2.0) and 50pl of this mixture was added
to wells of previously glutaraldehyde treated micro-
titre plates. These were dried overnight at 37°C in a
sterile microbiological safety cabinet to comply with
Health and Safety requirements.
The plates were then blocked with 0.02% gelatin
and washed with 0.05% Tween 20 in PBS
containing 0.2% casein. To each well, 100,l of a
400ngml- 1 monoclonal antibody conjugate with
phosphatase and diluted in PBS with Tween, was
added and incubated at 4°C overnight.
Following further washes, 100,l of substrate
buffer (one tablet of Sigma 104 phosphatase to Sml
of Diethanoline (BDH) 5% w/v+0.02,MMg L/2)
was added and incubated at 37°C in the dark for
30min. Plates were read at 405nm.
Assayfor CA125 and PLAP
Levels of CA125 were determined using a
commercially available kit (International CIS (UK)
Ltd., London) according to manufacturer's instruc-
tions, and serum PLAP was measured according to
an established assay method (Tucker et al., 1985).
Results
HMFGI and HMFG2 assay
Several parameters have been examined and our
findings (data not shown in this manuscript) were
that for HMFG1 and HMFG2 and using human
milk fat globule membrane HMFG and partially
deglycosylated HMFG (J. Taylor-Papadimitriou,
personal communication) as antigen we could
detect down to 2-4ng HMFG in serum. We used
this value as the operational cut-off level,
established by examining normal blood donors, the
cut-off point being the mean of all samples plus 2
s.d. Although results are expressed as optical
density units they can also be converted to ngl-l
HMFG antigen. For each assay a standard curve
was performed. We found (data not shown) that
the interassay and intraassay variations were always
< 10% and usually between 3-5%. Therefore serial
measurements of serum antigen levels could be
confidently performed as shown in Figures la-c.
Patients
The proportion of patients with ovarian adeno-
carcinoma with elevated antigen levels, compared to
control subjects is shown in Table I, the combined
sensitivity - any marker positive - reaching 95%.
Sensitivity was increased to 98.8% when a further
assay for placental alkaline phosphatase (PLAP)
was performed in 5 patients who had normal levels
of CA125, HMFG1, HMFG2 and active ovarian
cancer; three of these 5 patients had elevated serum
PLAP. CA125 was detected irrespective of
histological type, but of patients with mucinous
tumours HMFG1 was elevated, marginally, in only
one, whilst HMFG2 was elevated in none (Table
II). The sensitivity of HMFG1 and HMFG2 in
non-mucinous ovarian adenocarcinoma was 47/80
(59%) and 55/80 (69%) respectively. The absolute
serum levels of all three antigens was positively
correlated with increasing tumour burden (Table
III). Increasing sensitivity as tumour bulk increased
was more marked for CA125 than for HMFG2.
This was not seen for HMFG1 where the antigen
was detected as frequently in minimal residual
disease (<2cm maximum diam.) as in bulk residual
disease.
Correlation with clinical course of disease (Table
IV; Figure la-c), was good for all 3 antigens. No
patients who responded to chemotherapy had a
rising or persistently elevated CA125. Both patients
who demonstrated a rising serum HMFG1 level
and 2 out of 3 patients who demonstrated a rising
serum HMFG2 level despite clinical response later
relapsed. If serum levels were initially elevated then
HMFG1 and HMFG2 tended to fall more slowly
than CA125 in responding patients (Figure la) and
demonstrated evidence of chemoresistance earlier
(Figures lb,c).
Discussion
In this report we describe a new method with a low
pH step which enables the measurement of serum
tumour antigens detectable by monoclonal anti-
bodies HMFG1 and HMFG2 and compare them to
an existing radioimmunometric assay CA125.NEW IMMUNOASSAYS FOR OVARIAN CANCER 893
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Figure 1 (a) The rate of decline in serum concentration of tumour markers in a responding patient. HMFG2
falls more slowly than CA125. (b) Difference in the rate of decline or elevation in serum concentration of
tumour markers in a patient with initially static disease followed by disease progression. (c) Behaviour of the
three tumour markers in a patient who responded initially but progressed later. Although there is a fall in
CA125 followed by a rise, there was a continuous rise in HMFG1 and HMFG2 levels. * 0, CA125;
*--*, HMFG2; 0---- 0, HMFG1.
Table I The proportion (%) of patients and normal controls with elevated and
normal levels of serum antigens
CA125 HMFGJ HMFG2 All
>35uml-1 (>0.13OD) (>0.130D) markers
Apparently healthy
blood donors 1 6.25 3.1 7
patient n= 150
sera n= 150
Patients with
ovarian cancer 85 56 65 95
patient n=85
sera n=924
a I I
.. I
.011-1 0
,*-.,
-0, *-e
-1-
......
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Table II The comparative sensitivity of CA125, HMFG1 and HMFG2 in
ovarian tumours overall and by histology
Histology Total CA125 HMFGJ HMFG2
Type
Ovarian
Adenocarcinomas
Serous 37 31 (84) 19 (51) 25 (68)
Mucinous 5 4 (80) 1 (25) 0
Clear cell 5 5 (100) 3 (60) 2 (40)
Endometroid 12 7 (58) 7 (58) 9 (75)
Undifferentiated 26 24 (92) 18 (69) 18 (69)
Totals 85 71 (84) 48 (56) 55 (65)
Other ovarian
germ cell 4 1 2 3
Granulosa/sex chord 4 2 1 1
Percentages in parenthesis.
Table III The comparative sensitivity of CA125, HMFG1 and
HMFG2 by bulk of tumour before chemotherapy
Bulk oftumour No. CA125 HMFGJ HMFG2
<2cm 23 14 (6I)a 12 (52) 11 (48)
(111.7)b (0.129) (0.13)
2- 0cm 24 20 (83) 13 (54) 18 (75)
(254.8) (0.16) (0.171)
> 10cm 37 36 (97) 22 (58) 25 (67)
(1026) (0.226) (0.254)
a% positive, b=mean.
Table IV Changes in serial antigen levels
by response obtained
(A) Antigen response in patients static or
progressive disease
Antigen Fall Static Rise
CA125 1 15 9
HMFG1 1 12 12
HMFG2 1 12 12
(B) Antigen response in responding patients
Antigen Fall Static Rise
CA125 23 3a 0
HMFG1 7 17b 2
HMFG2 14 gc 3
aAll 3 normal throughout; b14 normal
throughout; '3 normal throughout.
This study confirms the previously demonstrated
utility of CA125 as a marker in ovarian cancer
(Bast et al., 1983; Canney et al., 1984). Approxi-
mately 85% of patients with active tumour have
elevated levels of CA125. However, using this new
method with a panel of HMFG1 and HMFG2 with
CA125 the sensitivity can be increased to 95%
without loss of specificity. Five patients had normal
levels of CA125, HMFG1, HMFG2 in spite of
having active ovarian cancer. Three of these five
patients had elevated serum placental alkaline phos-
phatase, PLAP. Thus the sensitivity using a panel
of four possible markers (CA125, HMFGI,
HMFG2 and PLAP) is 98.8%. Sensitivity of this
order provides increased confidence for clinical
management.
In patients with normal serum markers, no
additional information was provided by further
tests such as ultrasound and CT scanning. This
should allow for considerable financial savings toNEW IMMUNOASSAYS FOR OVARIAN CANCER 895
be made in that tumour markers cost £10£15 per
assay as compared to over £100 for ultrasound and
CT scanning. We do not know whether more
invasive methods such as second look laparotomy
provide more information regarding disease status
than does the assay for serum markers. Studies are
presently underway to determine this.
It was of interest that serial measurements of
HMFG1, HMFG2, CA125 and PLAP during
therapy showed different patterns of response for
the different antibodies. CA125 fell promptly after
therapy. HMFG1 and HMFG2 fell more slowly.
Patients with high levels of PLAP had a poor
prognosis in agreement with previous studies
(Doellgast & Homesley, 1984). These differences
may reflect cellular heterogeneity within a tumour
either in terms of sensitivity to therapy or in terms
of cell loss mechanisms.
Drying of serum samples at 37°C overnight does
not have any more Health and Safety implications
than when performing a conventional sandwich
assay for the measurement of serum markets
assuming that the drying process is carried out in a
microbiological safety cabinet.
In conclusion, the use of this new assay method
for tumour markers detected by antibodies
HMFGI and HMFG2, in conjunction with another
established assay CA125, is of value in the
management of patients with epithelial ovarian
cancer. Sera negative for HMFG1, HMFG2 and
CA125 should be tested for the presence of
placental alkaline phosphatase PLAP. If all markers
are negative then it is extremely unlikely that active
disease is present. Furthermore, in view of the high
positive rate in patients with breast cancer (Dhokia
et al., 1986) this panel of antibodies (HMFG1 and
HMFG2) should be tested for its potential as a
screening method for ovarian or breast cancer in
high risk asymptomatic patients.
We are grateful to the following for their help: K.
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